Synuclein-γ promotes migration of MCF7 breast cancer cells by activating extracellular-signal regulated kinase pathway and breaking cell-cell junctions

Zhuang,Qing; Liu,Caiyun; Qu,Like; Shou,Chengchao

doi:10.3892/mmr.2015.3799

Synuclein-γ promotes migration of MCF7 breast cancer cells by activating extracellular-signal regulated kinase pathway and breaking cell-cell junctions

Authors:
- Qing Zhuang
- Caiyun Liu
- Like Qu
- Chengchao Shou
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: May 19, 2015 https://doi.org/10.3892/mmr.2015.3799
Pages: 3795-3800

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Synuclein-γ (SNCG), a synuclein family member, promotes migration, invasion and metastasis of tumor cells; however, the mechanism remains unclear. The present study investigated the effect of SNCG on malignant phenotypes of MCF7 cells using cell proliferation analysis, cell migration assays and wound healing assays, and verified its effects on extracellular‑signal regulated kinase (Erk) activation and epithelial to mesenchymal transition‑related markers using western blotting. The results indicated that SNCG increased migration (P<0.05) but not proliferation (P=0.711) of MCF7 cells. It was also demonstrated that SNCG activated the Erk pathway and an inhibitor of Erk signaling significantly counteracted SNCG‑induced migration. Furthermore, it was shown that SNCG downregulated levels of tight junctions‑associated factors E‑cadherin and ZO‑1, while inhibiting the Erk pathway did not affect their levels. In conclusion, SNCG may promote MCF7 cell migration through activating the Erk pathway and breaking cell-cell junctions.

View Figures

View References

1	Ueda K, Fukushima H, Masliah E, et al: Molecular cloning of cDNA encoding an unrecognized component of amyloid in alzheimer disease. Proc Natl Acad Sci USA. 90:11282–11286. 1993. View Article : Google Scholar : PubMed/NCBI
2	Spillantini MG, Schmidt ML, Lee VM, et al: Alpha-synuclein in lewy bodies. Nature. 388:839–840. 1997. View Article : Google Scholar : PubMed/NCBI
3	Hashimoto M, Rockenstein E, Mante M, et al: Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 32:213–223. 2001. View Article : Google Scholar : PubMed/NCBI
4	Park JY and Lansbury PT: Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry. 42:3696–3700. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ji HJ, Liu YE, Jia T, et al: Identification of a breast cancer specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res. 57:759–764. 1997.PubMed/NCBI
6	Guo J, Shou C, Meng L, et al: Neuronal protein synuclein-γ predicts poor clinical outcome in breast cancer. Int J Cancer. 121:1296–1305. 2007. View Article : Google Scholar : PubMed/NCBI
7	Bruening W, Giasson BI, Klein-Szanto AJ, et al: Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 88:2154–2163. 2000. View Article : Google Scholar : PubMed/NCBI
8	Liu H, Liu W, Wu Y, et al: Loss of epigenetic control of synu-clein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res. 65:7635–7643. 2005.PubMed/NCBI
9	Iwaki H, Kageyama S, Isono T, et al: Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 95:955–961. 2004. View Article : Google Scholar : PubMed/NCBI
10	Liu C, Dong B, Lu AP, et al: Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcino-embryonic antigen. BMC Cancer. 10:3592010. View Article : Google Scholar
11	Guo J, Shou C, Meng L, et al: Neuronal protein synuclein-γ predicts poor clinical outcome in breast cancer. Int J Cancer. 121:1296–1305. 2007. View Article : Google Scholar : PubMed/NCBI
12	Wu K, Quan Z, Weng Z, et al: Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treat. 101:259–267. 2007. View Article : Google Scholar
13	Ye Q, Feng B, Peng YF, et al: Expression of γ-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116. World J Gastroenterol. 15:5035–5043. 2009. View Article : Google Scholar : PubMed/NCBI
14	Surgucheva IG, Sivak JM, Surguchov AP, et al: Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells. Arch Biochem Biophys. 410:167–176. 2003. View Article : Google Scholar : PubMed/NCBI
15	Pan ZZ, Bruening W and Godwin AK: Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. Int J Oncol. 29:289–295. 2006.
16	Seo JH, Rah JC, Choi SH, et al: Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16:1826–1828. 2002.PubMed/NCBI
17	Grunert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003. View Article : Google Scholar : PubMed/NCBI
18	Xie L, Law BK, Chytil AM, Brown KA, Aakre ME and Moses HL: Activation of the Erk pathway is required for TGF-β1-induced EMT in vitro. Neoplasia. 6:603–610. 2004. View Article : Google Scholar : PubMed/NCBI
19	Wang H, Wang HS, Zhou BH, et al: Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLoS One. 8:e566642013. View Article : Google Scholar
20	Pan ZZ, Bruening W, Godwin AK, et al: Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem. 277:35050–35060. 2002. View Article : Google Scholar : PubMed/NCBI
21	Liu C, Guo J, Qu L, et al: Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients. Cancer Lett. 269:148–158. 2008. View Article : Google Scholar : PubMed/NCBI
22	Cavallaro U and Christofori G: Cell adhesion and signaling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 4:118–132. 2004. View Article : Google Scholar : PubMed/NCBI
23	Elizabeth M, Christopher TC and Ian GM: Zonula occludens-a function in the assembly of tight junctions in Madin-Darby canine kidney epithelial cells. Mol Biol Cell. 17:1922–1932. 2006. View Article : Google Scholar
24	Surguchov A: Molecular and cellular biology of synucleins. Int Rev Cell Mol Biol. 270:225–317. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ye Q, Huang F, Wang XY, et al: Effects of γ-synuclein on the tumorigenicity and metastasis of colon cancer SW116 cells in vitro and in vivo. Oncol Rep. 30:2161–2170. 2013.PubMed/NCBI
26	Jiang Y, Liu YE, Lu A, et al: Stimulation of estrogen receptor signaling by γ-synuclein. Cancer Res. 63:3899–3903. 2003.PubMed/NCBI
27	Chen JY, Jiao L, Xu CL, et al: Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression. BMC Cancer. 12:5932012. View Article : Google Scholar : PubMed/NCBI
28	Jia T, Liu YE, Liu J and Shi YE: Stimulation of breast cancer invasion and metastasis by synuclein γ. Cancer Res. 59:742–747. 1999.PubMed/NCBI
29	Yilmaz M and Christofori G: EMT, the cytoskeleton and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI